trial

A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia

NCTId NCT02873208
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 266 (actual)
Sponsored by Alkermes, Inc.
Primary completion 2019-10-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
266 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2016-08-07
Primary completion
2019-10-17
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
ALKS 3831

Sponsors

Alkermes, Inc.Lead Sponsor

Investigators

1
Alkermes Medical Director, MDPrincipal Investigator

Sites

45 total
Little Rock, United StatesSpringdale, United StatesAnaheim, United StatesCerritos, United StatesCulver City, United StatesGarden Grove, United StatesGlendale, United StatesLemon Grove, United StatesLong Beach, United StatesOakland, United StatesOceanside, United StatesOrange, United States

Linked catalysts

1
A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With S — primary completion2019-10-17

Facts & assertions

4 sourced
Enrollment
266
Phase
PHASE3
Primary Completion Date
2019-10-17
Status
COMPLETED
relationships
The graph out of here
drug
ALKS 3831
drug
lead_sponsor
Alkermes, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Alkermes Medical Director, MD
person